Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 40

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 40
---
 incur large and immediate write-offs. |

| 20 |

We also may be unable to find
suitable acquisition candidates and may not be able to complete acquisitions on favorable terms, if at all, or obtain adequate financing
for such acquisitions. If we do complete an acquisition, this may not ultimately strengthen our competitive position or ensure that we
will not be viewed negatively by customers, financial markets or investors. Further, acquisitions could also pose numerous additional
risks to our operations, including:

| • | problems integrating the purchased business, products or technologies without substantial costs, delays 
 or other problems;                                                                                      |

| • | increases to our expenses; |

| • | the failure to have discovered undisclosed liabilities of the acquired asset or company for which we may 
 not be adequately indemnified;                                                                           |

| • | diversion of management’s attention from their day-to-day responsibilities and our core business; |

| • | inability to enforce indemnification and non-compete agreements; |

| • | the failure to successfully incorporate acquired products or technologies into our business; |

| • | the failure of the acquired business, products or technologies to perform as well as anticipated; |

| • | the failure to realize expected synergies and cost savings; |

| • | unexpected safety issues and/or clinical trial failure of the acquisition’s products; |

| • | harm to our operating results or financial condition, particularly during the first several reporting 
 periods after the acquisition is completed;                                                           |

| • | entrance into markets in which we have limited or no prior experience; and |

| • | potential loss of key employees or customers, particularly those of the acquired entity. |

We may not be able to complete
one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a
material adverse effect on our business, financial condition and results of operations.

Our future success is dependent on product development and the ability to successfully license our product candidates to partners who can seek regulatory approval and commercialization of our product candidates.

We continue to conduct research
and development for our product candidates and, to a lesser extent, clinical trials for certain of our product candidates; however there
can be no assurance that any of our targeted developments will be successful. We must develop functional products that address specific
market needs. We must therefore engage in new development activities, which may not produce innovative, commercially viable results in
a timely manner or at all. In addition, we may not be able to develop new technologies or identify specific market needs that are address